Monash & Virtus see market growth return

After a painful year, demand for assisted reproductive services is growing again. But it's the long term that matters.

This time last year, Monash IVF reported that total patient treatments in its key markets had fallen 3.7% on the prior year, compared to the 4% market growth assumed in its prospectus. Monash’s share price dropped 15%, while the stock of larger competitor Virtus Health fell 8%.

However, we considered the result ‘simply a short-term blip spurred by softer than expected industry figures’ and maintained our Buy recommendation (see Virtus Health and Monash still buys from 30 Oct 14 (Buy – $1.37)).



{{ twilioFailed ? 'SMS Code Failed to Send…' : 'An SMS verification code has been sent ...' }}

Hi {{ user.FirstName }}

Looks like you have already taken a free trial

Please enter your payment details

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to complete your SMS verification

We cannot send you a code via SMS to {{user.DayPhone}}

If you didn't receive SMS code please

SMS code cannot be sent due to: {{ twilioStatus }}

Please select one of the options below:

Looks you are already a member. Please enter your password to proceed

Please untick this box when using a public or shared device

Verify your mobile number to proceed...

Please check your mobile number below and press the Send Verification Code button. This will be used to complete your verification in the next step.

Please sign up for full access


Updating information

Please wait ...


{{ productPrice }} / day
( GST included )
Price $0
GST $0
Discount -{{productDiscount}}
TOTAL {{productPrice}}
  • Mastercard
  • Visa

Please click on the ACTIVATE button to finalise your membership


The email address you entered is registered with InvestSMART.

Please login or select "Don't know password"

Please untick this box when using a public or shared device

Register as a new member

(using a different email)

Related Articles